Akademska digitalna zbirka SLovenije - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources SI consortium. For full access, REGISTER.

1 2 3 4 5
hits: 721
1.
  • Cardiovascular and Renal Ou... Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
    Gerstein, Hertzel C; Sattar, Naveed; Rosenstock, Julio ... The New England journal of medicine, 09/2021, Volume: 385, Issue: 10
    Journal Article
    Peer reviewed
    Open access

    This trial compared weekly injections of efpeglenatide, an exendin-based glucagon-like peptide-1 receptor agonist, at a dose of 4 or 6 mg with placebo in participants with known type 2 diabetes and ...
Full text
Available for: CMK, UL

PDF
2.
  • Vericiguat in Patients with... Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
    Armstrong, Paul W; Pieske, Burkert; Anstrom, Kevin J ... The New England journal of medicine, 05/2020, Volume: 382, Issue: 20
    Journal Article
    Peer reviewed
    Open access

    Patients with chronic heart failure and a reduced ejection fraction were randomly assigned to the soluble guanylate cyclase stimulator vericiguat or placebo, in addition to guideline-based medical ...
Full text
Available for: CMK, UL

PDF
3.
  • Noncardiac Comorbidities in... Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction
    Mentz, Robert J., MD; Kelly, Jacob P., MD; von Lueder, Thomas G., MD, PhD ... Journal of the American College of Cardiology, 12/2014, Volume: 64, Issue: 21
    Journal Article
    Peer reviewed
    Open access

    Abstract Heart failure patients are classified by ejection fraction (EF) into distinct groups: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
4.
  • Pulmonary Hypertension in H... Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction : A Community-Based Study
    LAM, Carolyn S. P; ROGER, Véronique L; RODEHEFFER, Richard J ... Journal of the American College of Cardiology, 03/2009, Volume: 53, Issue: 13
    Journal Article
    Peer reviewed
    Open access

    This study sought to define the prevalence, severity, and significance of pulmonary hypertension (PH) in heart failure with preserved ejection fraction (HFpEF) in the general community. Although ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
5.
  • Iron deficiency across chro... Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management
    Cappellini, Maria Domenica; Comin-Colet, Josep; de Francisco, Angel ... American journal of hematology, 10/2017, Volume: 92, Issue: 10
    Journal Article
    Peer reviewed
    Open access

    Iron deficiency, even in the absence of anemia, can be debilitating, and exacerbate any underlying chronic disease, leading to increased morbidity and mortality. Iron deficiency is frequently ...
Full text
Available for: BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SBCE, SBMB, UL, UM, UPUK

PDF
6.
  • Global Cardiovascular Reser... Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection Fraction
    Borlaug, Barry A., MD; Olson, Thomas P., PhD; Lam, Carolyn S.P., MBBS ... Journal of the American College of Cardiology, 09/2010, Volume: 56, Issue: 11
    Journal Article
    Peer reviewed
    Open access

    Objectives The purpose of this study was to comprehensively examine cardiovascular reserve function with exercise in patients with heart failure and preserved ejection fraction (HFpEF). Background ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
7.
  • Effect of Vericiguat vs Pla... Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial
    Armstrong, Paul W; Lam, Carolyn S. P; Anstrom, Kevin J ... JAMA : the journal of the American Medical Association, 10/2020, Volume: 324, Issue: 15
    Journal Article
    Peer reviewed
    Open access

    IMPORTANCE: Patients with heart failure and preserved ejection fraction (HFpEF) are at high risk of mortality, hospitalizations, and reduced functional capacity and quality of life. OBJECTIVE: To ...
Full text
Available for: CMK

PDF
8.
  • The Global Health and Econo... The Global Health and Economic Burden of Hospitalizations for Heart Failure: Lessons Learned From Hospitalized Heart Failure Registries
    AMBROSY, Andrew P; FONAROW, Gregg C; GHEORGHIADE, Mihai ... Journal of the American College of Cardiology, 04/2014, Volume: 63, Issue: 12
    Journal Article
    Peer reviewed
    Open access

    Heart failure is a global pandemic affecting an estimated 26 million people worldwide and resulting in more than 1 million hospitalizations annually in both the United States and Europe. Although the ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
9.
  • Women’s Participation in Ca... Women’s Participation in Cardiovascular Clinical Trials From 2010 to 2017
    Jin, Xurui; Chandramouli, Chanchal; Allocco, Brooke ... Circulation (New York, N.Y.), 2020-February-18, 2020-Feb-18, 2020-02-18, 20200218, Volume: 141, Issue: 7
    Journal Article
    Peer reviewed
    Open access

    BACKGROUND:Cardiovascular disease is the leading cause of death among women worldwide, yet, women have historically been underrepresented in cardiovascular trials. METHODS:We systematically assessed ...
Full text
Available for: NUK, UL, UM, UPUK

PDF
10.
  • Rivaroxaban in Patients wit... Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease
    Zannad, Faiez; Anker, Stefan D; Byra, William M ... The New England journal of medicine, 10/2018, Volume: 379, Issue: 14
    Journal Article
    Peer reviewed
    Open access

    Patients with heart failure, coronary artery disease, and no atrial fibrillation were randomly assigned to receive 2.5 mg of rivaroxaban twice daily or placebo. Rivaroxaban did not have a significant ...
Full text
Available for: CMK, UL

PDF
1 2 3 4 5
hits: 721

Load filters